drugset / Trial / NCT00219076

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients

NCT00219076

Phase 3 Completed 504 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the blood pressure lowering effect and safety of aliskiren 150 mg used in combination with amlodipine 5 mg in patients with essential hypertension not adequately responsive to amlodipine 5 mg.

Timeline

Start
2005-02
Primary completion
2005-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 150 mg